[Federal Register Volume 74, Number 59 (Monday, March 30, 2009)]
[Notices]
[Pages 14138-14139]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-6933]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of Federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Method of Making a Vaccine

    Description of Technology: Current invention describes the methods 
to prepare vaccines, and to use such vaccines in the vaccination and 
treatment of human disease, e.g., the human immunodeficiency virus 
(HIV) infections and cancer. More specifically, the present invention 
provides a vaccine and method for making same which is effective to 
elicit a desired antibody against a target antigen comprising a primary 
immunogen and a secondary immunogen, wherein the primary immunogen is 
effective to elicit B cell receptors (BCRs) that are on the 
maturational pathway of the desired antibody and have an intermediate 
degree of somatic mutational diversity, and the secondary immunogen 
comprises an epitope of the desired target antibody and is effective to 
further diversify the BCRs sufficient to form mature BCRs having the 
identical or substantially identical sequence as the desired antibody.
    Applications: Treatment and prevention of HIV infection.
    Advantages: Novel methods to design vaccines for HIV treatment and 
prevention; May also be used for designing vaccines for cancer 
treatment.
    Development Status: In vitro data available.
    Market: HIV therapeutics and preventatives.
    Inventor: Dimiter S. Dimitrov (NCI).
    Publications:
    1. MY Zhang, Y Shu, S Phogat, X Xiao, F Cham, P Bouma, A Choudhary, 
YR Feng, I Sanz, S Rybak, CC Broder, GV Quinnan, T Evans, DS Dimitrov. 
Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab 
selected by sequential antigen panning of a phage display library. J 
Immunol Methods. 2003 Dec;283(1-2):17-25.
    2. MY Zhang, X Xiao, IA Sidorov, V Choudhry, F Cham, PF Zhang, P 
Bouma, M Zwick, A Choudhary, DC Montefiori, CC Broder, DR Burton, GV 
Quinnan Jr, DS Dimitrov. Identification and characterization of a new 
cross-reactive human immunodeficiency virus type 1-neutralizing human 
monoclonal antibody. J Virol. 2004 Sep;78(17):9233-9242.
    3. Z Zhu, AS Dimitrov, KN Bossart, G Crameri, KA Bishop, V 
Choudhry, BA Mungall, YR Feng, A Choudhary, MY Zhang, Y Feng, LF Wang, 
X Xiao, BT Eaton, CC Broder, DS Dimitrov. Potent neutralization of 
Hendra and Nipah viruses by human monoclonal antibodies. J Virol. 2006 
Jan;80(2):891-899.
    4. MY Zhang, V Choudhry, IA Sidorov, V Tenev, BK Vu, A Choudhary, H 
Lu, GM Stiegler, HW Katinger, S Jiang, CC Broder, DS Dimitrov. 
Selection of a novel gp41-specific HIV-l neutralizing human antibody by 
competitive antigen panning. J Immunol Methods. 2006 Dec 20;317(1-
2):21-30.
    5. V Choudhry, MY Zhang, IA Sidorov, JM Louis, I Harris, AS 
Dimitrov, P Bouma, F Cham, A Choudhary, SM Rybak, T Fouts, DA 
Montefiori, CC Broder, GV Quinnan Jr, DS Dimitrov. Cross-reactive HIV-1 
neutralizing monoclonal antibodies selected by screening of an immune 
human phage library against an envelope glycoprotein (gpI40) isolated

[[Page 14139]]

from a patient (R2) with broadly HIV-l neutralizing antibodies. 
Virology. 2007 Jun 20;363(1):79-90.
    6. Z Zhu, S Chakraborti, Y He, A Roberts, T Sheahan, X Xiao, LE 
Hensley, P Prabakaran, B Rockx, IA Sidorov, D Corti, L Vogel, Y Feng, 
JO Kim, LF Wang, R Baric, A Lanzavecchia, KM Curtis, GJ Nabel, K 
Subbarao, S Jiang, DS Dimitrov. Potent cross-reactive neutralization of 
SARS coronavirus isolates by human monoclonal antibodies. Proc Natl 
Acad Sci USA. 2007 Jul 17;104(29):12123-12128.
    7. Z Zhu, KN Bossart, KA Bishop, G Crameri, AS Dimitrov, JA 
McEachern, Y Feng, D Middleton, LF Wang, CC Broder, DS Dimitrov. 
Exceptionally potent cross-reactive neutralization of Nipah and Hendra 
viruses by a human monoclonal antibody. J Infect Dis. 2008 Mar 
15;197(6):846-853.
    8. MY Zhang, BK Vu, A Choudhary, H Lu, M Humbert, H Ong, M Alam, RM 
Ruprecht, G Quinnan, S Jiang, DC Montefiori, JR Mascola, CC Broder, BF 
Haynes, DS Dimitrov. Cross-reactive human immunodeficiency virus type 
1-neutralizing human monoclonal antibody which recognizes a novel 
conformational epitope on gp41 and lacks reactivity against self 
antigens. J Virol. 2008 Jul;82(14):6869-6879.
    Patent Status: U.S. Provisional Application No. 61/104,706 filed 11 
Oct 2008 (HHS Reference No. E-322-2008/0-US-01).
    Licensing Status: Available for licensing.
    Licensing Contact: Sally Hu, Ph.D.; 301-435-5606; <a href="/cdn-cgi/l/email-protection#4e063b1d0e232f27226020272660292138"><span class="__cf_email__" data-cfemail="662e1335260b070f0a48080f0e48010910">[email protected]</span></a>.
    Collaborative Research Opportunity: The National Cancer Institute 
is seeking statements of capability or interest from parties interested 
in collaborative research to further develop, evaluate, or 
commercialize this method. Please contact John D. Hewes, Ph.D. at 301-
435-3121 or <a href="/cdn-cgi/l/email-protection#4e262b392b3d240e232f27226020272660292138"><span class="__cf_email__" data-cfemail="87efe2f0e2f4edc7eae6eeeba9e9eeefa9e0e8f1">[email protected]</span></a> for more information.

Anti-Hepatitis C Virus Activity of the Protein Scytovirin (SVN)

    Description of Technology: The invention provides compositions and 
methods of use for potent anti-HCV protein scytovirin to prevent and 
treat HCV infections. Currently there is neither effective treatment 
nor vaccine against HCV infection and chronic HCV infection may lead to 
liver cancer and death. Scytovirin can be used alone or in combination 
with other anti-HCV drugs for HCV treatment and prevention.
    Applications: The treatment and prevention of HCV infections.
    Advantages: Potent anti-HCV activity; Can be applied both 
systematically or locally.
    Development Status: In vitro data available.
    Market: HCV therapeutics and preventatives.
    Inventors: Barry R. O'Keefe et al. (NCI).
    Publications: Data collection and manuscripts may be submitted in 
2009.
    Patent Status: U.S. Provisional Application No. 61/137,511 filed 31 
Jul 2008 (HHS Reference No. E-161-2008/0-US-01).
    Related Technology: HHS Reference No. E-017-2002/0--Scytovirins and 
Related Conjugates, Antibodies, Compositions, Nucleic Acids, Vectors, 
Host Cells, Methods of Production and Methods of Using Scytovirin.
    Licensing Status: Available for licensing.
    Licensing Contact: Sally Hu, Ph.D.; 301-435-5606, <a href="/cdn-cgi/l/email-protection#571f2204173a363e3b79393e3f79303821"><span class="__cf_email__" data-cfemail="276f5274674a464e4b09494e4f09404851">[email protected]</span></a>.
    Collaborative Research Opportunity: The National Cancer Institute 
CCR Molecular Targets Development Program is seeking statements of 
capability or interest from parties interested in collaborative 
research to further develop, evaluate, or commercialize this 
technology. Please contact John D. Hewes, Ph.D. at 301-435-3121 or 
<a href="/cdn-cgi/l/email-protection#8be3eefceef8e1cbe6eae2e7a5e5e2e3a5ece4fd"><span class="__cf_email__" data-cfemail="4e262b392b3d240e232f27226020272660292138">[email protected]</span></a> for more information.

    Dated: March 19, 2009.
 Richard U. Rodriguez,
 Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. E9-6933 Filed 3-27-09; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>